Hypoxic markersImaging hypoxia after oxygenation-modification: Comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors
Section snippets
Animals and tumor models
The human head and neck squamous cell carcinoma xenograft tumor line SCCNij3, and the human glioblastoma tumor lines E102 and E106 were used for these experiments. Viable 1 mm3 tumor pieces were implanted subcutaneously in the abdominal flank of athymic BALB/C nu/nu mice and tumors were used for the experiments at a diameter of 8–9 mm. All mice were kept in accordance with institutional guidelines. All experiments were approved by the Animal Experiments Committee of the Radboud University
[18F]FMISO autoradiography and pimonidazole staining
Fig. 1 depicts examples of hypoxia visualized after pimonidazole immunohistochemistry, segmentation of the pimonidazole signal and [18F]FMISO autoradiography of the SCCNij3 and E106 tumors. As results after clamping for 30 or 60 min were similar, these were pooled for the analysis. In the SCCNij3 tumors, visualization of pimonidazole revealed a significant increase of the hypoxic fraction (obtained after segmentation of the gray-value image) after clamping and a non-significant decrease of the
Discussion
A well established method for quantification of hypoxia is the use of hypoxic cell markers such as pimonidazole. Immunohistochemical detection of pimonidazole in tissue sections has been shown to predict for prognosis in advanced stage head and neck cancer [16]. A possible alternative to this method is PET imaging of the hypoxic tracer [18F]FMISO. In various solid tumors hypoxia was detected using [18F]FMISO-PET [7], [17], [25], [29]. The advantage of imaging hypoxia with a [18F]FMISO-PET scan
Conclusion
Pimonidazole labeling can be used to detect viable hypoxic cells at pO2 levels below 10 mm Hg. By visualizing pimonidazole, hypoxia can be studied with a high spatial resolution providing detailed information at the microscopic level. [18F]FMISO can be used as PET-tracer to study hypoxia at the global level in tumors in situ. In the present study, pimonidazole labeling was used for validation of [18F]FMISO autoradiography. This pimonidazole signal reflects only reduced and bound marker. The
Acknowledgements
This research was supported by EC FP6 funding (Biocare – Contract no. LSHC-CT-2004-505785) and by Grant KUN 2003-2901 of the Dutch Cancer Society. We thank Dr. J.A. Raleigh for the gift of anti-pimonidazole MAb, Dr. H. Rennen for the synthesis of [18F]FMISO and the collaborators from the Central Animal Laboratory for biotechnical assistance and animal care.
References (32)
- et al.
Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours
Radiother Oncol
(2003) - et al.
Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide
Radiother Oncol
(1999) - et al.
Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers
Radiother Oncol
(2003) - et al.
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON
Radiother Oncol
(2006) - et al.
Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole
Int J Radiat Oncol Biol Phys
(1992) - et al.
Feasibility of measuring oxygen tension in uterine cervix carcinoma
Eur J Cancer
(1992) - et al.
An efficient radiosynthesis of [18F]fluoromisonidazole
Appl Radiat Isot
(1993) - et al.
Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
Radiother Oncol
(1996) - et al.
A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy
Radiother Oncol
(2000) - et al.
Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas
Radiother Oncol
(2003)
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study
Radiother Oncol
Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients
Int J Radiat Oncol Biol Phys
Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis
Int J Radiat Oncol Biol Phys
Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging
Int J Radiat Oncol Biol Phys
Influence of oxygen concentration and pH on expression of hypoxia induced genes
Radiother Oncol
[18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors
Nucl Med Biol
Cited by (65)
Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy
2019, Radiotherapy and OncologyCitation Excerpt :Still, HV1.6 does not necessarily resemble the local oxygenation of the tumour that is evaluated by a biopsy. Besides, for a large cohort of HNSCC xenograft tumour lines imaged with FMISO autoradiography and pimonidazole immunohistochemistry, it was demonstrated that not all microscopic hypoxic areas were visualised by FMISO-PET [43,44], i.e. the biopsy may contain additional information. The correlation between hypoxia-related molecular expressions or staining intensities and hypoxia PET was considered in a few retrospective studies before.
FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients
2019, Radiotherapy and OncologyResidual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging
2017, Radiotherapy and OncologyCitation Excerpt :Moreover, recurrent loco-regional disease in some patients was found to occur outside the volume demarcated by pre-treatment FMISO-PET. Besides, it was shown in a large cohort of HNSCC xenograft tumour lines, imaged with FMISO autoradiography and pimonidazole immunohistochemistry, that not all microscopic hypoxic areas were visualised by FMISO, which provided more global information [55,56]. Another preclinical study on HNSCC xenografts suggested that tumour hypoxia determined by nitroimidazole-based biomarkers may be associated with a generally more radioresistant tumour phenotype, beyond biochemically mediated cellular radioresistance (the so called oxygen effect) [57].
Hypoxia imaging in gliomas with <sup>18</sup>F-fluoromisonidazole PET: Toward clinical translation
2015, Seminars in Nuclear MedicineBiology of hypoxia
2015, Seminars in Nuclear Medicine18F-FMISO PET-guided dose escalation with multifield optimization intensity-modulated proton therapy in nasopharyngeal carcinoma
2023, Asia-Pacific Journal of Clinical Oncology